First cohort responds well to Pharmaxis cancer treatment drug - next phase of clinical trial fully subscribed - The Sentiment
Actinium Pharma on Twitter: "Actinium's Pivotal Phase 3 SIERRA trial fully enrolled. Data update in 4Q 2021 with topline data expected in mid-2022. Iomab-B showing clear value proposition through 75% enrollment. Learn